FDA Warns Public Against the Use of Unregistered Drugs “Adcort Plus (Drops Solution)” and “Silwax (Drops Solution)”

FDA Warns Public Against the Use of Unregistered Drugs “Adcort Plus (Drops Solution)” and “Silwax (Drops Solution)”


MANILA, PHILIPPINES – The Food and Drug Administration advises the public against the use of the following unregistered drug products:


The abovementioned drug products pose potential danger or inquiry to the consuming public and the importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009.

In the interest of protecting public health and safety, and pursuant to Section 12 of R.A. No. 9711, the field Food and Drug Regulation Officers of this Office are hereby ordered to seize the aforementioned unregistered drug products found in the market.

All establishment and outlets are hereby warned against selling and/or dispensing the above identified products. Anyone found selling the said products will be penalized.

Likewise, all local government units and law enforcement agencies are requested to ensure that these products are not sold or offered for sale in their localities or area of jurisdiction.

All consumers are advised to purchase their medications only from FDA-licensed establishments. Please note that in addition to inspection of establishments, product evaluation, registration, and testing are measures that the government undertakes to ensure the quality, safety and efficacy of health products. Please look for the FDA Registration number on the product label, Moreover, please be reminded that drug products registered with FDA Philippines bear in their labels information in English and/or Filipino for all consumers to understand.

For more information and inquiries, please email info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly email via report@fda.gov.ph or you may call the telephone number (02) 807-8275. For any suspected adverse drug reaction (ADR), please email adr@fda.gov.ph.

Leave a Reply

Your email address will not be published. Required fields are marked *